Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20679740 | 0.80 | KDM4E (0.47) | TSHRHTTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL15882100 | 0.78 | ALDH1A1 (0.42) | HTTL3MBTL1ALDH1A1MAPK1NPC1 | |
| SCHEMBL29453753 | 0.78 | TSHR (0.57) | TSHRALDH1A1HSD17B10UCHL1USP2 | |
| SCHEMBL11662 | 0.78 | TSHR (0.57) | TSHRALDH1A1HSD17B10UCHL1USP2 | |
| SCHEMBL16111775 | 0.76 | HSD17B10 (0.44) | TSHRHTTALDH1A1HSD17B10TP53 | |
| SCHEMBL20723148 | 0.76 | TSHR (0.50) | TSHRHTTALDH1A1HSD17B10TP53 | |
| SCHEMBL12215764 | 0.76 | TSHR (0.50) | TSHRALDH1A1HSD17B10UCHL1USP2 | |
| SCHEMBL24107508 | 0.74 | ALDH1A1 (0.36) | TSHRHTTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL21198942 | 0.74 | GSK3A (0.42) | TSHRL3MBTL1ALDH1A1HSD17B10UCHL1 | |
| SCHEMBL16065191 | 0.74 | UCHL1 (0.42) | ALDH1A1UCHL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | TSHR 4310/4885HTT 3861/4885L3MBTL1 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.